# Araris Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/araris-biotech

- Industry: Biotechnology
- Headquarters: Zurich, Switzerland
- Website: www.ararisbiotech.com
- Total disclosed funding: $41M
- Latest round: Series A (Oct 4, 2022)
- Investors on record: 9

## About

Araris Biotech AG develops advanced antibody-drug conjugate technology, focusing on its proprietary AraLinQ™ linker platform for efficient drug delivery to targeted tissues, primarily in oncology.Founded in 2019 and headquartered in Zurich, Switzerland, Araris Biotech AG specializes in developing novel antibody-drug conjugate technology. The company was founded by Philipp Spycher. In March 2025, the company became the target of a TRADE SALE, securing an acquisition deal with Taiho Pharmaceutical for USD 400.000 mn, with the potential for additional payments of up to USD 740.000 mn based on milestone achievements. Araris has participated in 6 total deals, indicating a steady trajectory in securing partnerships and funding.Araris Biotech AG specializes in the development of proprietary antibody-drug conjugate (ADC) technology, particularly their innovative AraLinQ™ linker platform. This technology facilitates the rapid and efficient attachment of drug payloads to off-the-shelf antibodies in a single step, eliminating the need for re-engineering antibodies. The primary function of these ADCs is to deliver highly potent anti-cancer drugs directly to targeted diseased tissues while minimizing harm to healthy cells. Their product offerings aim to address critical problems associated with existing ADC technologies, such as poor stability, high heterogeneity, and limited solubility. Araris serves a global client base, including pharmaceutical companies and research institutions involved in cancer treatment, with applications spanning markets in North America, Europe, and parts of Asia, particularly Japan and South Korea.Araris Biotech AG generates revenue primarily through strategic partnerships and research agreements with leading pharmaceutical companies, including notable collaborations with Taiho Pharmaceutical and Johnson & Johnson. These partnerships often involve licensing agreements for the use of Araris' proprietary technology in developing next-generation ADCs. The structure of these transactions typically consists of upfront payments, milestone payments based on development progress, and potential royalties on future sales of commercialized products. While specific pricing structures for their flagship products, including their AraLinQ™ technology, have not been disclosed, the revenue model is established around collaborative research and development initiatives, reflecting the company's focus on B2B partnerships within the biopharmaceutical sector.Araris Biotech AG's recent acquisition by Taiho Pharmaceutical is expected to enhance its oncology portfolio through the integration of its ADC technology. The company plans to utilize the USD 400.000 mn from the TRADE SALE to expand its research efforts and develop new ADC products. Additionally, Araris aims to penetrate new markets in Asia, particularly targeting growth in Japan and South Korea, with plans to launch innovative ADC therapies by 2026. The strategic direction is geared towards enhancing collaborations and increasing the scale of operations to meet the global demand for advanced cancer therapies.

## Funding rounds

- Series A, Oct 4, 2022, $24M — Schroders Capital, Vi Partners, b2venture, Redalpine, 4BIO Capital Partners, Wille AG, Pureos Bioventures, Institute for Follicular Lymphoma Innovation
- Seed, Oct 22, 2020, $14M — Schroders Capital, Vi Partners, b2venture, Redalpine, 4BIO Capital Partners, Kinled Holding, Pureos Bioventures
- Seed, Aug 20, 2019, $2.6M — Schroders Capital, Vi Partners, Redalpine

## Investors

- Schroders Capital (https://capitalatlas.ai/funds/schroders-capital) — Seed, Series A
- Vi Partners (https://capitalatlas.ai/funds/vi-partners) — Seed, Series A
- Redalpine (https://capitalatlas.ai/funds/redalpine) — Seed, Series A
- b2venture (https://capitalatlas.ai/funds/b2venture) — Seed, Series A
- 4BIO Capital Partners (https://capitalatlas.ai/funds/4bio-capital-partners) — Seed, Series A
- Kinled Holding — Seed
- Pureos Bioventures (https://capitalatlas.ai/funds/pureos-bioventures) — Seed, Series A
- Wille AG — Series A
- Institute for Follicular Lymphoma Innovation — Series A